Search Within

John Vito K Deluca

Formats
  1. Journal Article (6)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (8)
  2. Genitourinary Oncology Service (8)
  3. Solid Tumor Oncology Division (8)
  4. Body Imaging Service (5)
  5. Radiology, Department of (5)
  6. Biostatistics Service (4)

More Groups

People
  1. Robert Motzer (8)
  2. Nicole Leoce (7)
  3. Gnanamba Kondagunta (5)
  4. Jennifer Bacik (4)
  5. Lawrence Schwartz (4)
  6. Sujata Patil (4)

More People

Years
  1. 2016 (1)
  2. 2010 (1)
  3. 2008 (3)
  4. 2007 (1)
  5. 2006 (2)
Publications
  1. Journal of Clinical Oncology (3)
  2. Investigational New Drugs (2)
  3. Cancer (1)
  4. Clinical Genitourinary Cancer (1)
  5. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. Springer (2)
  3. Elsevier Inc. (1)
  4. Oxford University Press (1)
  5. Wiley Blackwell (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma
    Journal Article

    Carlo, M. I.; Molina, A. M.; Lakhman, Y.; Patil, S.; Woo, K.; Deluca, J.; Lee, C. H.; Hsieh, J. J.; Feldman, D. R.; Motzer, R. J.; more...
    The Oncologist (2016)

    Fulltext@MSK | Save
  • Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: Implications for clinical trial design and interpretation
    Journal Article

    Patil, S.; Ishill, N.; Deluca, J.; Motzer, R. J.
    Cancer (2010)

    Fulltext@MSK | Save
  • Trends in Memorial Sloan-Kettering Cancer Center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Patil, S.; Ishill, N. M.; Deluca, J.; Motzer, R. J.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma
    Journal Article

    Patel, P. H.; Kondagunta, G. V.; Schwartz, L.; Ishill, N.; Bacik, J.; Deluca, J.; Russo, P.; Motzer, R. J.
    Investigational New Drugs (2008)

    Fulltext@MSK | Save
  • Phase II trial of pegylated interferon-α2b in patients with advanced renal cell carcinoma
    Journal Article

    Feldman, D. R.; Kondagunta, G. V.; Schwartz, L.; Patil, S.; Ishill, N.; Deluca, J.; Russo, P.; Motzer, R. J.
    Clinical Genitourinary Cancer (2008)

    Fulltext@MSK | Save
  • Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors
    Journal Article

    Kondagunta, G. V.; Bacik, J.; Sheinfeld, J.; Bajorin, D.; Bains, M.; Reich, L.; Deluca, J.; Budnick, A.; Ishill, N.; Mazumdar, M.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response
    Meeting Abstract

    Kondagunta, G. V.; Bacik, J.; Ishill, N.; Reuter, V.; Schwartz, L. H.; Korkola, J.; Deluca, J.; Sweeney, S.; Chaganti, R. S. K.; Motzer, R. J.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
    Journal Article

    Ronnen, E. A.; Kondagunta, G. V.; Ishill, N.; Sweeney, S. M.; DeLuca, J. K.; Schwartz, L.; Bacik, J.; Motzer, R. J.
    Investigational New Drugs (2006)

    Fulltext@MSK | Save